JAK2 inhibitors tested in clinical trials in patients with myelofibrosis
Hg indicates hemoglobin; Plts, platelets; TLS, tumor lysis syndrome; BMR, bone marrow response; and CMR, complete molecular response.
* Non-JAK targets inhibited at administered doses of drug with potentially relevant clinical effect.
† Notable and clinically relevant or distinct, in some cases leading to study termination or halted drug development.
‡ Bone marrow response either in terms of CR of histopathologic abnormalities and resolution of reticulin/collagen fibrosis.
§ Complete molecular response of JAK2V617F, MPL, or CALR.
Sign In or Create an Account